Search peptides, terms, sources/
Research source · 2008

Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia

About this source

Kind
Research
Design
Human clinical trial
Population
GAD/neurasthenia patients
Sample size
62 (30 Selank, 32 medazepam)
Primary or secondary
primary
Peer review
peer reviewed
Retraction status
None known
Date checked
14 August 2026

Limitations

Active-comparator trial, not placebo-controlled; single trial. Adverse-event data have not been checked against the full primary text.

Cited in

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.